(Q36580608)

15 August 2017

1 reference

title

Inhibition of dipeptidylpeptidase IV activity as a therapy of type 2 diabetes (English)

1 reference

15 August 2017

1 reference

Brian D Green

1

1 reference

15 August 2017

Peter R Flatt

series ordinal

2

1 reference

15 August 2017

Clifford J Bailey

series ordinal

3

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 September 2006

1 reference

Expert Opinion on Emerging Drugs

15 August 2017

published in

1 reference

15 August 2017

volume

11

1 reference

15 August 2017

issue

3

1 reference

15 August 2017

page(s)

525-539

1 reference

Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

Antibiotic treatment for uncomplicated neuropathic forefoot ulcers in diabetes: a controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

Reduced hepatic insulin extraction in response to gastric inhibitory polypeptide compensates for reduced insulin secretion in normal-weight and normal glucose tolerant first-degree relatives of type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

Glucagon-like peptide 1: a potent glycogenic hormone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

Inositolphosphoglycans are possible mediators of the glucagon-like peptide 1 (7-36)amide action in the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

Inhibition of gastric inhibitory polypeptide signaling prevents obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

Glucagon-like peptide-1(7-36) amide (GLP-1) enhances insulin-stimulated glucose metabolism in 3T3-L1 adipocytes: one of several potential extrapancreatic sites of GLP-1 action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

The metabolite generated by dipeptidyl-peptidase 4 metabolism of glucagon-like peptide-1 has no influence on plasma glucose levels in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

Dipeptidyl peptidase IV-resistant [D-Ala(2)]glucose-dependent insulinotropic polypeptide (GIP) improves glucose tolerance in normal and obese diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

Oral antihyperglycemic therapy for type 2 diabetes: scientific review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

21 January 2018

Oral Antidiabetic Agents

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

Mouse fibroblast-activation protein--conserved Fap gene organization and biochemical function as a serine protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

Structural and kinetic analysis of the substrate specificity of human fibroblast activation protein alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

Post-proline-cleaving peptidases having DP IV like enzyme activity. Post-proline peptidases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

Kinetic investigation of human dipeptidyl peptidase II (DPPII)-mediated hydrolysis of dipeptide derivatives and its identification as quiescent cell proline dipeptidase (QPP)/dipeptidyl peptidase 7 (DPP7).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

Catalytic properties and inhibition of proline-specific dipeptidyl peptidases II, IV and VII

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

Amino-terminal truncation of chemokines by CD26/dipeptidyl-peptidase IV. Conversion of RANTES into a potent inhibitor of monocyte chemotaxis and HIV-1-infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

Natural truncation of RANTES abolishes signaling through the CC chemokine receptors CCR1 and CCR3, impairs its chemotactic potency and generates a CC chemokine inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

Role of hypothalamic neuropeptide Y in feeding and obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

The gut hormone peptide YY regulates appetite

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

Pituitary adenylate cyclase-activating polypeptide (PACAP) is an islet substance serving as an intra-islet amplifier of glucose-induced insulin secretion in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

Pituitary adenylate cyclase-activating peptide (PACAP): assessment of dipeptidyl peptidase IV degradation, insulin-releasing activity and antidiabetic potential.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

Kinetic study of the processing by dipeptidyl-peptidase IV/CD26 of neuropeptides involved in pancreatic insulin secretion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

The role of dipeptidyl peptidase IV in the cleavage of glucagon family peptides: in vivo metabolism of pituitary adenylate cyclase activating polypeptide-(1-38).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

Dipeptidyl peptidase IV (DPIV/CD26) degradation of glucagon. Characterization of glucagon degradation products and DPIV-resistant analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

Improved glucose tolerance via enhanced glucose-dependent insulin secretion in dipeptidyl peptidase IV-deficient Fischer rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

Improvement of high fat-diet-induced insulin resistance in dipeptidyl peptidase IV-deficient Fischer rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

Dipeptidyl peptidase IV inhibitors for the treatment of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

Applications of dipeptidyl peptidase IV inhibitors in diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

Enteroinsular axis of db/db mice and efficacy of dipeptidyl peptidase IV inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

The combination of metformin and a dipeptidyl peptidase IV inhibitor prevents 5-fluorouracil-induced reduction of small intestine weight

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

Hematopoietic stimulation by a dipeptidyl peptidase inhibitor reveals a novel regulatory mechanism and therapeutic treatment for blood cell deficiencies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

Association of systemic chemokine concentrations with impaired glucose tolerance and type 2 diabetes: results from the Cooperative Health Research in the Region of Augsburg Survey S4 (KORA S4).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

Evaluation of the effect of gain on the meal response of an automated closed-loop insulin delivery system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

Reduced serum dipeptidyl peptidase-IV after metformin and pioglitazone treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

Enhanced secretion of glucagon-like peptide 1 by biguanide compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

Endoproteolysis of glucagon-like peptide (GLP)-1 (7-36) amide by ectopeptidases in RINm5F cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

Incretins, insulin secretion and Type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

Successive cleavage of N-terminal Arg1--Pro2 and Lys3-Pro4 from substance P but no release of Arg1-Pro2 from bradykinin, by X-Pro dipeptidyl-aminopeptidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

Degradation of endomorphin-2 at the supraspinal level in mice is initiated by dipeptidyl peptidase IV: an in vitro and in vivo study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

Modulation of endomorphin-2-induced analgesia by dipeptidyl peptidase IV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation, normal T cell expressed and secreted) by dipeptidyl peptidase IV (CD26)-mediated cleavage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

Anti-HIV-1 and chemotactic activities of human stromal cell-derived factor 1alpha (SDF-1alpha) and SDF-1beta are abolished by CD26/dipeptidyl peptidase IV-mediated cleavage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

Truncation of macrophage-derived chemokine by CD26/ dipeptidyl-peptidase IV beyond its predicted cleavage site affects chemotactic activity and CC chemokine receptor 4 interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

Glucagon-like peptide-1(7–37) has a larger volume of distribution than glucagon-like peptide-1(7–36)amide in dogs and is degraded more quickly in vitro by dog plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

Development of potent and selective dipeptidyl peptidase II inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.11.3.525

10.1517/14728214.11.3.525

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference